Future Fertility collaborates with FutureLife on expansive multi-country study to assess egg quality using AI 

We’re delighted to announce our new partnership with FutureLife, a world-renowned Prague-based fertility clinic network with over 45 clinics across ten countries. Our collaboration will kick off with a large, multi-phase, multi-clinic study to demonstrate the efficacy of our AI-powered oocyte assessment tool, MAGENTA™, and will emphasize the applicability of the tool in clinical practice. This comprehensive study will be conducted across nine clinics located in Ireland, the Netherlands, Czechia, Spain, Romania, Finland, and the UK. By incorporating a diverse range of clinics and patient demographics, the study aims to ensure the generalizability of our model across multiple clinical scenarios and patient groups undergoing IVF.

The study will also explore the correlation of oocyte quality with other clinical variables throughout the IVF process, leveraging this large and diverse dataset to advance our understanding of how oocyte quality can impact IVF treatments to improve patient outcomes.   

“We are excited to collaborate with Future Fertility on this expansive study, which aligns with our mission to provide the most advanced and personalized care to our patients,” said Štěpán Machač, Chief Medical Officer of FutureLife. 

The IVF journey can be an arduous process for patients, and in recent years, AI companies have emerged to tackle the measurement and optimization of various steps in the IVF process, enabling embryologists and clinicians to take a more individualized approach to IVF treatment planning. While AI solutions are largely being adopted by clinics to support personalized selection of protocols, sperm and embryos, assessing individualized oocyte quality remains an impossible task for embryology teams due to the lack of a standardized system to visually assess the impact of oocyte quality on IVF outcomes.   

“We believe that the integration of AI-powered solutions in reproductive medicine has the potential to revolutionize IVF treatments and improve success rates,” remarks Simon Fishel, the Chair of FutureLife’s Scientific Advisory Board. “We look forward to the insights and advancements that this collaboration will bring.”   

Our CE- and UK-approved solution is the first of its kind to utilize AI to analyze 2D images of oocytes and predict their likelihood of forming a blastocyst – a crucial stage in the development of a viable embryo. Our deep learning model, built and tested using a dataset of over 70,000 oocyte images and their outcomes from eight countries so far, has been clinically validated as a non-invasive system to objectively assess the quality of individual oocytes.   

“With Future Fertility’s technology, we can provide clinicians and patients with valuable insights into oocyte quality, empowering them to make more informed decisions about their reproductive options,” said Christy Prada, CEO of Future Fertility. “We are thrilled to collaborate with FutureLife, a leader in the field of reproductive medicine, to further validate our technology and expand our dataset to ensure its applicability across different clinical scenarios.”   

FutureLife’s network of clinics, with their state-of-the-art facilities and experienced medical teams, are renowned for providing the highest standard of personalized care to patients through the adoption of the latest technologies in reproductive precision medicine. As one of the largest and fastest-growing fertility service providers globally, performing over 45,000 IVF cycles annually, FutureLife is at the forefront of advancing the field.